Short Interest in CalciMedica Inc. (NASDAQ:CALC) Drops By 60.5%

CalciMedica Inc. (NASDAQ:CALC) saw a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 127,684 shares, a drop of 60.5% from the August 15th total of 323,241 shares. Currently, 2.6% of the company’s shares are sold short. Based on an average daily volume of 99,862 shares, the days-to-cover ratio is currently 1.3 days.

CalciMedica Stock Performance

NASDAQ CALC traded down $0.02 on Tuesday, hitting $1.98. The stock had a trading volume of 55,047 shares, compared to its average volume of 198,834. The company’s 50-day moving average is $3.25 and its two-hundred day moving average is $3.43. The stock has a market cap of $13.52 million, a price-to-earnings ratio of -0.29 and a beta of 0.83. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 1.67. CalciMedica has a one year low of $1.87 and a one year high of $36.00.

CalciMedica (NASDAQ:CALC) last announced its earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.97. On average, analysts expect that CalciMedica will post -5.25 earnings per share for the current year.

Insider Buying and Selling at CalciMedica

In other news, Director Fred A. Middleton purchased 49,794 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was bought at an average cost of $4.00 per share, for a total transaction of $199,176.00. Following the completion of the purchase, the director directly owned 212,654 shares of the company’s stock, valued at $850,616. The trade was a 30.57% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 28.25% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CalciMedica

An institutional investor recently raised its stake in CalciMedica stock. 180 Wealth Advisors LLC grew its holdings in CalciMedica Inc. (NASDAQ:CALC) by 297.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 126,500 shares of the company’s stock after acquiring an additional 94,650 shares during the period. 180 Wealth Advisors LLC owned 0.80% of CalciMedica worth $68,000 as of its most recent SEC filing.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Weiss Ratings raised shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. UBS Group reiterated a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. Wall Street Zen lowered shares of CalciMedica from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Guggenheim began coverage on shares of CalciMedica in a research note on Thursday, August 20th. They issued a “buy” rating on the stock. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, CalciMedica has a consensus rating of “Hold” and an average target price of $50.00.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.